Mylan 1Q Revenues: $2.5 billion (-7%) 1Q Loss: $25 million (earnings were $87.1 million) Comments: North America sales were $922.9 million, down 6% primarily driven by changes in the competitive environment and the impact of the Morgantown plant remediation activities, partially offset by new product sales, including Wixela Inhuband Fulphila (biosimilar to Neulasta), and increased market share on Glatiramer Acetate Injection. Rest of World segment sales were $642.4 million, up 3%. Europe segm...